• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[中国肝癌发病率及趋势分析]

[Analysis of liver cancer incidence and trend in China].

作者信息

Zuo Tingting, Zheng Rongshou, Zeng Hongmei, Zhang Siwei, Chen Wanqing

机构信息

National Cancer Center, National Office for Cancer Prevention and Control, Beijing 100021, China.

National Cancer Center, National Office for Cancer Prevention and Control, Beijing 100021, China; Email:

出版信息

Zhonghua Zhong Liu Za Zhi. 2015 Sep;37(9):691-6.

PMID:26813435
Abstract

OBJECTIVE

The national population-based cancer registration data were used to analyze the liver cancer incidence and trend in China, in order to provide advise for making further strategy on liver cancer prevention and control.

METHODS

Liver cancer data of 2011 were retrieved from the database of the National Cancer Registry. The incident cases of liver cancer were estimated using age-specific rate by urban or rural areas and gender according to the national population in 2011. Liver cancer incidence data from 22 cancer registries were used to analyze the incidence trend during 2000-2011.

RESULTS

The estimates of new cases of liver cancer were about 356 thousand in China in 2011. The incidence rate was 26.39/10(5,) and the age-standardized incidence rates by Chinese standard population and by world population were 19.48/10(5) and 19.10/10(5,) respectively.There was an increasing trend of incidence rate of liver cancer in China during 2000-2011 with an average annual percentage change(AAPC) of 1.0% (95%CI: 0.5%-1.4%), 1.2% (95%CI: 0.7%-1.8%)in urban areas and 1.1% (95%CI: 0.5%-1.8%) in rural areas. After age standardization, the incidence rate was significantly decreased, with an AAPC of -1.8% (95%CI: -2.4% to -1.2%), -1.6% (95%CI: -2.2% to -0.9%) in urban and -1.4% (95%CI: -2.5% to -0.3%) in rural areas.

CONCLUSIONS

Liver cancer is a common cancer in China. As changing in people's dietary habits and implementing neonatal HBV vaccination for years, the exposure to risk factors is reducing, and age-standardized incidence rate is decreasing. While cardinal number of population is big and aging population is growing rapidly in the country, trend of incidence rate is increasing, and the burden of liver cancer is still high in China.

摘要

目的

利用全国基于人群的癌症登记数据,分析中国肝癌的发病情况及趋势,为制定进一步的肝癌防控策略提供建议。

方法

从全国癌症登记数据库中检索2011年肝癌数据。根据2011年全国人口,采用按城乡和性别划分的年龄别发病率估算肝癌发病病例。利用22个癌症登记处的肝癌发病数据,分析2000 - 2011年期间的发病趋势。

结果

2011年中国肝癌新发病例估计约为35.6万例。发病率为26.39/10万,中国标准人口和世界人口的年龄标准化发病率分别为19.48/10万和19.10/10万。2000 - 2011年中国肝癌发病率呈上升趋势,年均变化百分比(AAPC)为1.0%(95%CI:0.5% - 1.4%),城市地区为1.2%(95%CI:0.7% - 1.8%),农村地区为1.1%(95%CI:0.5% - 1.8%)。年龄标准化后,发病率显著下降,城市地区AAPC为 - 1.8%(95%CI: - 2.4%至 - 1.2%),农村地区为 - 1.4%(95%CI: - 2.5%至 - 0.3%)。

结论

肝癌是中国常见的癌症。随着人们饮食习惯的改变和多年来实施新生儿乙肝疫苗接种,危险因素暴露减少,年龄标准化发病率下降。但由于中国人口基数大且老龄化人口快速增长,发病率仍呈上升趋势,肝癌负担依然较重。

相似文献

1
[Analysis of liver cancer incidence and trend in China].[中国肝癌发病率及趋势分析]
Zhonghua Zhong Liu Za Zhi. 2015 Sep;37(9):691-6.
2
[Mortality and survival analysis of liver cancer in China].[中国肝癌的死亡率与生存分析]
Zhonghua Zhong Liu Za Zhi. 2015 Sep;37(9):697-702.
3
[Incidence and trend analysis of esophageal cancer in China].[中国食管癌的发病率及趋势分析]
Zhonghua Zhong Liu Za Zhi. 2016 Sep 23;38(9):703-8. doi: 10.3760/cma.j.issn.0253-3766.2016.09.013.
4
[Trend analysis on incidence and age at diagnosis for lung cancer in cancer registration areas of China, 2000-2014].[2000 - 2014年中国癌症登记地区肺癌发病率及诊断年龄趋势分析]
Zhonghua Yu Fang Yi Xue Za Zhi. 2018 Jun 6;52(6):579-585. doi: 10.3760/cma.j.issn.0253-9624.2018.06.005.
5
[Incidence and mortality of laryngeal cancer in China, 2014].[2014年中国喉癌的发病率和死亡率]
Zhonghua Zhong Liu Za Zhi. 2018 Oct 23;40(10):736-743. doi: 10.3760/cma.j.issn.0253-3766.2018.10.004.
6
Rural-urban, sex variations, and time trend of primary liver cancer incidence in China, 1988-2005.中国 1988-2005 年原发性肝癌发病率的城乡、性别差异和时间趋势。
Eur J Cancer Prev. 2013 Sep;22(5):448-54. doi: 10.1097/CEJ.0b013e32835de82a.
7
[Incidence and mortality of liver cancer in China: an analysis on data from the National Registration System between 2003 and 2007].中国肝癌的发病率与死亡率:基于2003年至2007年国家登记系统数据的分析
Zhonghua Liu Xing Bing Xue Za Zhi. 2012 Jun;33(6):547-53.
8
[Report of cancer epidemiology in China, 2015].《2015年中国癌症流行病学报告》
Zhonghua Zhong Liu Za Zhi. 2019 Jan 23;41(1):19-28. doi: 10.3760/cma.j.issn.0253-3766.2019.01.005.
9
[Disease burden of colorectal cancer in China: any changes in recent years?].[中国结直肠癌的疾病负担:近年来有何变化?]
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Oct 10;41(10):1633-1642. doi: 10.3760/cma.j.cn112338-20200306-00273.
10
[Report of Cancer Incidence and Mortality in China, 2014].《2014年中国癌症发病与死亡报告》
Zhonghua Zhong Liu Za Zhi. 2018 Jan 23;40(1):5-13. doi: 10.3760/cma.j.issn.0253-3766.2018.01.002.

引用本文的文献

1
Spatiotemporal Trends in the Incidence of Gastrointestinal Neoplasms in Wuwei City of Northwestern China From 1995 to 2016: A Hospital-Based Retrospective Observational Study.1995年至2016年中国西北武威市胃肠道肿瘤发病率的时空趋势:一项基于医院的回顾性观察研究
Front Oncol. 2021 Sep 3;11:712857. doi: 10.3389/fonc.2021.712857. eCollection 2021.
2
Prognostic gene biomarker identification in liver cancer by data mining.通过数据挖掘鉴定肝癌的预后基因生物标志物
Am J Transl Res. 2021 May 15;13(5):4603-4613. eCollection 2021.
3
Fasting Blood Glucose, Cholesterol, and Risk of Primary Liver Cancer: The Kailuan Study.
空腹血糖、胆固醇与原发性肝癌风险:开滦研究。
Cancer Res Treat. 2021 Oct;53(4):1113-1122. doi: 10.4143/crt.2020.817. Epub 2021 Jan 19.
4
Probabilistic risk assessment of dietary exposure to aflatoxin B in Guangzhou, China.中国广州膳食摄入黄曲霉毒素 B 的概率风险评估。
Sci Rep. 2020 May 14;10(1):7973. doi: 10.1038/s41598-020-64295-8.
5
Effects and mechanism of Lanthanum Citrate on the proliferation and apoptosis of hepatocellular carcinoma cell line SMMC-7721.柠檬酸镧对肝癌细胞系 SMMC-7721 增殖和凋亡的影响及其作用机制。
Turk J Gastroenterol. 2020 Mar;31(3):264-271. doi: 10.5152/tjg.2020.18800.
6
Decreased DC-SIGNR expression in hepatocellular carcinoma predicts poor patient prognosis.肝细胞癌中DC-SIGNR表达降低预示患者预后不良。
Oncol Lett. 2020 Jan;19(1):69-76. doi: 10.3892/ol.2019.11074. Epub 2019 Nov 11.
7
Population-Based Incidence, Mortality, And Survival For Gastrointestinal Cancers During 2006-2016 In Wuhan, Central China.2006 - 2016年中国中部武汉市胃肠道癌症的人群发病率、死亡率及生存率
Cancer Manag Res. 2019 Oct 29;11:9233-9241. doi: 10.2147/CMAR.S209925. eCollection 2019.
8
Epidermal growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1) suppressed the growth of hepatocellular carcinoma cells by promoting Semaphorin 3B(SEMA3B).富含表皮生长因子的纤维连接蛋白样细胞外基质蛋白 1(EFEMP1)通过促进 SEMA3B(Semaphorin 3B)来抑制肝癌细胞的生长。
Cancer Med. 2019 Jun;8(6):3152-3166. doi: 10.1002/cam4.2144. Epub 2019 Apr 11.
9
Icotinib inhibits the proliferation of hepatocellular carcinoma cells in vitro and in vivo dependently on EGFR activation and PDL1 expression.埃克替尼在体外和体内均通过依赖表皮生长因子受体(EGFR)激活和程序性死亡受体配体1(PDL1)表达来抑制肝癌细胞的增殖。
Onco Targets Ther. 2018 Nov 21;11:8227-8237. doi: 10.2147/OTT.S179844. eCollection 2018.